Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...

An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is ...

The U.S. FDA’s decision to grant breakthrough device designation for Bivacor Inc.’s titanium total artificial heart (TAH) ...

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s BNT-327 in a deal possibly worth over $11 ...

Shares of Lyra Therapeutics Inc. soared more than 310% on data from its second phase III trial testing drug-device candidate ...

In yet another China antibody-drug conjugate (ADC) deal, Astellas Pharma Inc. is inlicensing a phase I/II ADC targeting ...

Biopharma’s nonprofit deal and grant activity continues to settle into a post-pandemic rhythm, with both showing a sustained ...

Several 5-HT4 receptor (5-HT4R) agonists are approved for treating chronic idiopathic constipation (CIC) by stimulating ...

The polarization of macrophages is crucial in modulating the tumor microenvironment and impacting cancer development. Long ...

Bronchodilators are front-line weapons against asthma and chronic obstructive pulmonary disorder. The search continues for ...

More phase III data coursed through the annual American Society of Clinical Oncology (ASCO) conference on Sunday, as ...

Despite the advancement of AI and machine learning technologies and their incorporation into cancer treatment and drug ...